Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Alpelisib hydrochloride
Price: Check
Purity: 98.0%
Stocking Period: 10 Day
Contact: Yang
Email: sales@echemcloud.com

1584128-91-5

1584128-91-5 structure

1584128-91-5 structure

Name: Alpelisib hydrochloride
Chemical Name: Alpelisib hydrochloride
CAS Number: 1584128-91-5
Molecular Formula: C₁₉H₂₃ClF₃N₅O₂S
Molecular Weight: 477.93
Catalog: Signaling Pathways PI3K/Akt/mTOR PI3K
Create Date: 2019-10-07 22:35:52
Modify Date: 2025-08-25 15:15:57
Alpelisib hydrochloride (BYL-719 hydrochloride) is a potent and selective PI3Kα inhibitor with IC50s of 5 nM, 250 nM, 290 nM and 1200 nM for p110α, p110γ, p110δ, and p110β, respectively[1].

Name	Alpelisib hydrochloride

Description	Alpelisib hydrochloride (BYL-719 hydrochloride) is a potent and selective PI3Kα inhibitor with IC50s of 5 nM, 250 nM, 290 nM and 1200 nM for p110α, p110γ, p110δ, and p110β, respectively[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> PI3K/Akt/mTOR >> PI3K
In Vitro	Alpelisib (BYL-719) potently inhibits the 2 most common PIK3CA somatic mutations (H1047R, E545K; IC50s~4 nM). Alpelisib potently inhibits Akt phosphorylation in cells transformed with PI3Kα (IC50=74±15 nM) and shows significant reduced inhibitory activity in PI3Kβ or PI3Kδ isoforms transformed cells (≥15-fold compared with PI3Kα)[2]. Alpelisib (BYL-719, 0-50 μM; 72 hours) inhibits the cell growth of osteosarcoma cell lines MG63, HOS, POS-1 and MOS-J in a dose-dependent manner[3]. Alpelisib (BYL-719) significantly alters the distribution of cell cycle phases. Alpelisib (BYL-719, 25 μM; 18 hours) induces a cell cycle arrest in the G0/G1 phase of human and murine osteosarcoma cell lines[3]. Cell Proliferation Assay[3] Cell Line: MG63, HOS, POS-1, MOS-J Concentration: 10, 20, 30, 40, 50 μM Incubation Time: 72 hours Result: Inhibited the cell growth of all osteosarcoma cell lines tested in a dose-dependent manner with IC50s of 6-15 µM and with IC90s of 24-42 µM. Cell Cycle Analysis[3] Cell Line: MG63, HOS, POS-1, MOS-J Concentration: 25 μM Incubation Time: 18 hours Result: Induced a cell cycle arrest in the G0/G1 phase of human and murine osteosarcoma cell.
In Vivo	Alpelisib (BYL-719) (12.5 mg/kg and 50 mg/kg for C57Bl/6J mice; 50 mg/kg for female Rj:NMRI-nude mice; oral administration; daily) significantly reduces tumor volumes and deposition of ectopic bone matrix[3]. Alpelisib has moderate terminal elimination half-life (t1/2=2.9±0.2 h) for rat (1 mg/kg, iv)[1]. Animal Model: A 5-week-old female Rj:NMRI-nude mice with human HOS-MNNG osteosarcoma cells; A 5-week-old male C57Bl/6J mice with mouse MOS-J osteosarcoma cells[3] Dosage: 12.5 mg/kg and 50 mg/kg for C57Bl/6J mice; 50 mg/kg for female Rj:NMRI-nude mice Administration: Oral administration; daily Result: Significantly reduced tumor volumes and simultaneously reduced tumor growth. Animal Model: Female Sprague Dawley rats [1] Dosage: 1 mg/kg (Pharmacokinetic Study) Administration: I.V. Result: T1/2=2.9±0.2 hours.
References	[1]. Furet P, et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3741-8. [2]. Fritsch C, et al. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther. 2014 May;13(5):1117-29. [3]. Gobin B, et al. BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. Int J Cancer. 2015 Feb 15;136(4):784-96.

Molecular Formula	C₁₉H₂₃ClF₃N₅O₂S
Molecular Weight	477.93

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.